Poxel S.A.

Poxel S.A. is a biopharmaceutical company dedicated to the development of innovative treatments for metabolic disorders. The company's primary focus is on addressing unmet medical needs within the realm of metabolic diseases, particularly targeting type 2 diabetes and non-alcoholic steatohepatitis (NASH). By harnessing their expertise in energy metabolism and signaling pathways, Poxel S.A. develops novel therapeutics that offer potential breakthroughs in managing these chronic conditions. Operating in the dynamic biopharmaceutical sector, Poxel S.A. has a portfolio that underscores the importance of metabolic research, as type 2 diabetes and NASH represent significant health challenges worldwide. The company's approach is characterized by a commitment to pioneering research and development, leveraging its proprietary technologies to deliver treatments that have the potential to improve the quality of life for patients. With a collaborative mindset, Poxel partners with other industry leaders to further enhance its research and commercial opportunities. Headquartered in Lyon, France, Poxel S.A.’s contributions to the pharmaceutical industry emphasize the critical role of innovation in tackling widespread metabolic disorders.